Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review.
Mariana Campello De Oliveira, Mariana Capelo Vides, Dângela Layne Silva Lassi, Julio Torales, Antonio Ventriglio, Henrique Silva Bombana, Vilma Leyton, Cintia de Azevedo-Marques Périco, André Brooking Negrão, André Malbergier, João Maurício Castaldelli-Maia
Brain Sciences June 24, 2023 DOI: 10.3390/brainsci13070990 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Population | Humans (from 64 articles, including 10 original papers and 54 case studies) |
| Keywords | Ab-fubinaca Ab-pinaca Adb Akb Apica Chmica Eam Hu Jwh K2 Mam Mdmb Pb Rcs Spice Ur Win Xlr Synthetic cannabinoid |
| Key findings | Synthetic cannabinoids, especially AB-CHMINACA and MDMB-CHMICA, are associated with death, tachycardia, seizures, and higher neuropsychiatric symptoms in third-generation SCs, with greater toxicity and longer-lasting effects than THC. |
Abstract
(1)
Background: Synthetic cannabinoids (SCs) are emerging drugs of abuse sold as 'K2', 'K9' or 'Spice'. Evidence shows that using SCs products leads to greater health risks than cannabis. They have been associated with greater toxicity and higher addiction potential unrelated to the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). Moreover, early cases of intoxication and death related to SCs highlight the inherent danger that may accompany the use of these substances. However, there is limited knowledge of the toxicology of Spice ingredients. This systematic review intends to analyze the toxicity of SCs compounds in Spice/K2 drugs. (2)
Methods: Studies analyzing synthetic cannabinoid toxicity and dependence were included in the present review. We searched the PubMed database of the US National Library of Medicine, Google Scholar, CompTox Chemicals, and Web of Science up to May 2022. (3)
Results: Sixty-four articles reporting the effects of synthetic cannabinoids in humans were included in our review. Ten original papers and fifty-four case studies were also included. Fourteen studies reported death associated with synthetic cannabinoid use, with AB-CHMINACA and MDMB-CHMICA being the main reported SCs. Tachycardia and seizures were the most common toxicity symptoms. The prevalence of neuropsychiatric symptoms was higher in third-generation SCs. (4)
Conclusion: SCs may exhibit higher toxicity than THC and longer-lasting effects. Their use may be harmful, especially in people with epilepsy and schizophrenia, because of the increased risk of the precipitation of psychiatric and neurologic disorders. Compared to other drugs, SCs have a higher potential to trigger a convulsive crisis, a decline in consciousness, and hemodynamic changes. Therefore, it is crucial to clarify their potential harms and increase the availability of toxicology data in both clinical and research settings.
Citations in the library
Cited by 2
- New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects. International Journal of Molecular Sciences August 31, 2024
- Pharmaco-toxicological effects of the synthetic cannabinoids 4F-ABUTINACA, SDB-005, and JWH-018 in mice. In vitro and in vivo studies. European Journal of Pharmacology April 1, 2025
Cites 12
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology: Clinical and Experimental July 1, 2013
- Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study British Journal of Pharmacology November 22, 2017
- Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis Psychopharmacology January 26, 2021
- A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence Frontiers in Psychiatry May 19, 2022
and 7 more in the library